|
Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Clinical research trials and Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H. Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H clinical trial. Human subjects frequently get the finest healthcare available for their Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H  Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
For Condition: Plasma Cell Dyscrasia,Myelodysplastic Disorders,Leukemia,Multiple Myeloma,Lymphoproliferative Disorders
Status: Recruiting
Sponsor(s): Baylor College of Medicine , The Methodist Hospital,Texas Children's Hospital
Synopsis: 1) To assess the treatment related mortality of allogeneic stem cell transplantation with non-myeloablative therapy incorporating the lymphodepleting MAb CAMPATH-1H, in patients with hematological diseases and renal cell carcinoma not eligible for conventional (myeloablative) therapy. 2) To assess the time to engraftment and incidence of graft failure in patients receiving this transplant regimen. 3) To assess the safety, pharmacokinetics and immunologic activity of CAMPATH-1H when used as part of a subablative conditioning regimen.
Details: This is a two arm study in which outcomes will be assessed independently in recipients of HLA matched sibling transplants and recipients of unrelated or mismatched family donor transplants, although both groups will receive identical treatments. The following will be given to the patient after admission: Day - 6: Total body irradiation Day - 5 to - 2: Fludarabine and Campath 1H Day - 1: Day of rest Day 0: Stem cell transplant (infusion)
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /70 Years
Genders: Both
Protocol Entry Criteria: Inclusion criteria 1. Diagnosis of myelodysplastic disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia and Hodgkins Disease) or Renal Cell Carcinoma. 2. Conditions that increase treatment related mortality (need one or more to be eligible): a) Greater to or equal to 50 years of age. b) EF of less than 45% c) DLCO less than 50% of FEV1 50-75% of predicted value. d) Diabetes Mellitus e) Renal Insufficiency (but creatine clearance not less than 25ml/min). f) Prior recent history of systemic fungal infection. g) 3rd or greater remission of AML or ALL h) More than 1 year of diagnosis (CML or Myeloma patients) i) Multiple types of treatment regimens. (equal to or more than 3) j) Prior autologous or allogeneic stem cell transplantation. k) Significant grade III or IV neurologic or hepatic toxicity from previous treatment. l) No matched sibling donor. 3. Available healthy donor without any contraindications for donation. 5/6 or 6/6 related donor. 5/6 or 6/6 unrelated donor (molecular typing for DRB1) 4. Patient and/or responsible person able to understand consent. 5. Age between birth and 70 years. 6. For women of childbearing potential, negative pregnancy test. Exclusion criteria 1. Pregnant and lactating women. 2. HIV positive patient 3. Uncontrolled intercurrent infection 4. Refractory AML, or ALL 5. Untreated Blast Crisis for CML 6. Uncontrolled High-grade lymphoproliferative disease/lymphoma. 7. Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater) 8. Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater) 9. Hemodialysis dependent 10. Active Hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3 x normal. 11. Unstable Cerebral vascular disease and recent hemorrhagic stroke (less than 6 months) 12. Active CNS disease from hematological disorder.
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
GeorgeCarrum, Principal Investigator, Baylor College of Medicine
Texas Children's Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting George Carrum 713-394-6250
The Methodist Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting George Carrum 713-394-6250
Additional Information:
Study ID Numbers: H8714; DIMSUM
Study Start Date: June 2000
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048412
Other Lymphoproliferative Disorders Studies:
1. Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
Related Studies:
Other Lymphoproliferative Disorders Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Stem Cell Transplant for Patients with Blood Malignancy Using Donors and Less Toxic Chemotherapy with CAMPATH 1H
|
|
|
|
|
|
|
|
